 |
| Bill Gates |
Thanks to a Series B round from Wellcome Trust and the Bill & Melinda Gates Foundation, U.K. biotech Kymab has some new vaccine research plans. Each organization has pledged $20 million to support the company's Kymouse technology, a genetically engineered mouse platform that allows scientists to generate human antibodies against a range of targets. And with the new funds, Kymab will join up with the Gates Foundation to search for new vaccine antigens, focusing at first on malaria and HIV. Release | More from FierceBiotech